<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063552</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2021-10021</org_study_id>
    <secondary_id>NCI-2021-10021</secondary_id>
    <secondary_id>EA3202</secondary_id>
    <secondary_id>EA3202</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <nct_id>NCT05063552</nct_id>
  </id_info>
  <brief_title>Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers</brief_title>
  <official_title>A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II/III compares the standard chemotherapy alone to adding bevacizumab to standard&#xD;
      chemotherapy, or a combination of just bevacizumab and atezolizumab in treating patients with&#xD;
      head and neck cancers that have spread to other places in the body (advanced stage).&#xD;
      Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune&#xD;
      system attack the cancer, and may interfere with the ability of tumor cells to grow and&#xD;
      spread. Bevacizumab and cetuximab are monoclonal antibodies that may interfere with the&#xD;
      ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin,&#xD;
      carboplatin, and docetaxel, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading. The&#xD;
      addition of bevacizumab and/or atezolizumab could shrink or stabilize head and neck cancers&#xD;
      or stop them from growing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus&#xD;
      cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II.&#xD;
      To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to&#xD;
      the superior arm from the phase II portion of the protocol. (Phase III)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as&#xD;
      combined positive score (CPS) &gt;= 20% on all arms of treatment.&#xD;
&#xD;
      II. To evaluate the toxicity of each arm of treatment.&#xD;
&#xD;
      IMAGING OBJECTIVES:&#xD;
&#xD;
      I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission&#xD;
      tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard&#xD;
      uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor&#xD;
      volume) and expression of PD-L1 expression (Low versus high, defined as CPS &lt; 20 versus CPS&#xD;
      &gt;= 20).&#xD;
&#xD;
      II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict&#xD;
      treatment response at nine to twelve weeks post-treatment, PFS, and OS.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1&#xD;
      expressions (Low versus high - defined as CPS &lt; 20 versus CPS &gt;= 20).&#xD;
&#xD;
      OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 3 arms.&#xD;
&#xD;
      ARM A: Patients receive cetuximab intravenously (IV) over 30-60 minutes on days 1, 8, and 15,&#xD;
      docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment&#xD;
      repeats every 21 days for up to 6 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles&#xD;
      repeat every 21 days for 2 years in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM B: Patients receive bevacizumab IV over 30-90 on day 1, docetaxel IV over 1 hour on day&#xD;
      1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6&#xD;
      cycles in the absence of disease progression or unacceptable toxicity. Patients then receive&#xD;
      bevacizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM C: Patients receive bevacizumab IV over 30-90 on day 1 and atezolizumab over 30-60&#xD;
      minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE III: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive cetuximab IV over 30-60 minutes on days 1, 8, and 15, docetaxel IV&#xD;
      over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21&#xD;
      days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days&#xD;
      for 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II&#xD;
      trial.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 3&#xD;
      months if patient is &lt; 2 years from randomization and every 6 months if patient is 2-5 years&#xD;
      from randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 12, 2022</start_date>
  <completion_date type="Anticipated">December 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2027</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) (Phase III)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be compared using a stratified log rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in the subset of patients with high PD-L1 expression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 18F-FDG PET and CT neck imaging biomarkers</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of treatment response</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>Determined by 18FDG-PET/CT and CT neck imaging biomarkers.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression</measure>
    <time_frame>Up to 5 years</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Metastatic Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Metastatic Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Lip and Oral Cavity Carcinoma</condition>
  <condition>Metastatic Nasal Cavity Squamous Cell Carcinoma</condition>
  <condition>Metastatic Nasopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Pharyngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Sinonasal Squamous Cell Carcinoma</condition>
  <condition>Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Recurrent Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Recurrent Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Lip and Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Recurrent Nasopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Pharyngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Sinonasal Squamous Cell Carcinoma</condition>
  <condition>Stage IV Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IV Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IV Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IV Nasopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IV Sinonasal Cancer AJCC v8</condition>
  <condition>Stage IVA Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVA Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVA Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVA Nasopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVA Sinonasal Cancer AJCC v8</condition>
  <condition>Stage IVB Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVB Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVB Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVB Nasopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVB Sinonasal Cancer AJCC v8</condition>
  <condition>Stage IVC Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVC Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVC Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVC Sinonasal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab intravenously (IV) over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 on day 1, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II, Arm C (Bevacizumab, Atezolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 on day 1 and atezolizumab over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in Arm B or C above based on results of the Phase II trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm C (Bevacizumab, Atezolizumab)</arm_group_label>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <other_name>MPDL 3280A</other_name>
    <other_name>MPDL 328OA</other_name>
    <other_name>MPDL-3280A</other_name>
    <other_name>MPDL3280A</other_name>
    <other_name>MPDL328OA</other_name>
    <other_name>RG7446</other_name>
    <other_name>RO5541267</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)</arm_group_label>
    <arm_group_label>Phase II, Arm C (Bevacizumab, Atezolizumab)</arm_group_label>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <other_name>ABP 215</other_name>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar ABP 215</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar GB-222</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar Mvasi</other_name>
    <other_name>Bevacizumab Biosimilar MYL-1402O</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>Bevacizumab Biosimilar Zirabev</other_name>
    <other_name>Bevacizumab-awwb</other_name>
    <other_name>Bevacizumab-bvzr</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Mvasi</other_name>
    <other_name>MYL-1402O</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
    <other_name>Zirabev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)</arm_group_label>
    <arm_group_label>Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)</arm_group_label>
    <arm_group_label>Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)</arm_group_label>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)</arm_group_label>
    <arm_group_label>Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)</arm_group_label>
    <other_name>Cetuximab Biosimilar CDP-1</other_name>
    <other_name>Cetuximab Biosimilar CMAB009</other_name>
    <other_name>Cetuximab Biosimilar KL 140</other_name>
    <other_name>Chimeric Anti-EGFR Monoclonal Antibody</other_name>
    <other_name>Chimeric MoAb C225</other_name>
    <other_name>Chimeric Monoclonal Antibody C225</other_name>
    <other_name>Erbitux</other_name>
    <other_name>IMC-C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)</arm_group_label>
    <arm_group_label>Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)</arm_group_label>
    <arm_group_label>Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)</arm_group_label>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)</arm_group_label>
    <arm_group_label>Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)</arm_group_label>
    <arm_group_label>Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)</arm_group_label>
    <arm_group_label>Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)</arm_group_label>
    <other_name>Docecad</other_name>
    <other_name>RP56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Taxotere Injection Concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have histologically confirmed squamous cell carcinoma of the head and&#xD;
             neck (HNSCC) (excluding SCC of salivary glands, and skin&#xD;
&#xD;
          -  Patient must have measurable disease as defined by Response Evaluation Criteria in&#xD;
             Solid Tumors RECIST version (v)1.1. Measurements must be obtained within 4 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Patient must be &gt;= 18 years of age&#xD;
&#xD;
          -  Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Patient must have received prior therapy with an immune checkpoint inhibitor (ICI) in&#xD;
             the first-line setting for recurrent/metastatic disease with at least stable disease&#xD;
             for at least 12 weeks by Immune-Modified (iRECIST). Prior combination immunotherapies&#xD;
             are permitted, but patient must not have had any prior chemotherapy, cetuximab or any&#xD;
             prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab,&#xD;
             sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have&#xD;
             completed any prior investigational therapy at least 28 days prior to randomization&#xD;
&#xD;
               -  NOTE: Patients who received chemotherapy or cetuximab in combination with&#xD;
                  radiation for curative-intent treatment of locally-advanced disease and did not&#xD;
                  progress for at least 6 months thereafter, will not be excluded&#xD;
&#xD;
          -  Patient must have PD-L1 expression &gt;= 1% by CPS in the tumor and/or immune cells&#xD;
&#xD;
               -  NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263&#xD;
                  assay. Where this is not feasible, any using their preferred Clinical Laboratory&#xD;
                  Improvement Act (CLIA)-certified assay will be accepted. It is preferred for&#xD;
                  standard of care (SOC) PD-L1 assessments to be done on post-first line ICI&#xD;
                  samples if available, but SOC PD-L1 assessments on pre-ICI samples will be&#xD;
                  accepted for eligibility&#xD;
&#xD;
          -  Patient must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document. Patients with impaired decision-making capacity (IDMC) who&#xD;
             have a legally authorized representative (LAR) or caregiver and/or family member&#xD;
             available will also be considered eligible&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL (must be obtained =&lt; 14 days prior to protocol randomization)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL (must be obtained =&lt; 14 days prior to&#xD;
             protocol randomization)&#xD;
&#xD;
          -  Lymphocyte &gt;= 500/mcL (must be obtained =&lt; 14 days prior to protocol randomization)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL (must be obtained =&lt; 14 days prior to protocol randomization)&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt; 9 g/dL (must be obtained =&lt; 14 days prior to protocol&#xD;
             randomization) (Note: Patient may be transfused to meet this criteria)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.0 x institutional upper limit of normal (ULN) (=&lt; 5.0 x&#xD;
             institutional ULN if hepatic metastases present or =&lt; 3 x ULN for patients with known&#xD;
             Gilbert's disease) (must be obtained =&lt; 14 days prior to protocol randomization)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional ULN (&lt; 5.0 x institutional ULN if hepatic metastases present)&#xD;
             (must be obtained =&lt; 14 days prior to protocol randomization)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 x institutional ULN (&lt; 5.0 x institutional ULN if hepatic&#xD;
             or bone metastases present) (must be obtained =&lt; 14 days prior to protocol&#xD;
             randomization)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x institutional ULN (must be obtained =&lt; 14 days prior to protocol&#xD;
             randomization)&#xD;
&#xD;
          -  Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium &gt; 1.5 mmol/L,&#xD;
             calcium &gt; 12 mg/dL or corrected serum calcium &gt; ULN) must have their calcium levels&#xD;
             corrected prior to randomization&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral&#xD;
             therapy with undetectable viral load within 6 months of randomization are eligible for&#xD;
             this trial&#xD;
&#xD;
          -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral&#xD;
             load must be undetectable on suppressive therapy, if indicated&#xD;
&#xD;
          -  Patients with a history of hepatitis C virus (HCV) infection must have been treated&#xD;
             and cured. For patients with HCV infection who are currently on treatment, they are&#xD;
             eligible if they have an undetectable HCV viral load&#xD;
&#xD;
          -  Patients with treated brain metastases are eligible if follow-up brain imaging after&#xD;
             central nervous system (CNS)-directed therapy shows no evidence of progression.&#xD;
             Patients must not have untreated brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient must not have a history of &gt;= grade 3 immune-related adverse event on prior&#xD;
             ICI therapy. Patients who developed grade 3 endocrinopathies but are now stable on&#xD;
             hormone supplementation and/or a daily prednisone dose of =&lt; 10 mg (or equivalent&#xD;
             doses of another glucocorticoid), will be permitted on this trial&#xD;
&#xD;
          -  Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined&#xD;
             as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating&#xD;
             ICI and associated with clinical deterioration&#xD;
&#xD;
          -  Patient must not have any of the following criteria due to the possibility of&#xD;
             increased risk for tumor bleeding with bevacizumab therapy:&#xD;
&#xD;
               -  Prior carotid bleeding,&#xD;
&#xD;
               -  Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by&#xD;
                  imaging studies,&#xD;
&#xD;
               -  Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as&#xD;
                  shown unequivocally by imaging studies,&#xD;
&#xD;
               -  Any prior history of bleeding related to the current head and neck cancer,&#xD;
&#xD;
               -  History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode&#xD;
                  of coughing) within 3 months prior to randomization&#xD;
&#xD;
          -  Patient must not have uncontrolled hypertension, a history of hypertensive crisis or&#xD;
             hypertensive encephalopathy, or a history of grade 4 thromboembolism&#xD;
&#xD;
          -  Patient must not have a history of coagulopathy or hemorrhagic disorders&#xD;
&#xD;
          -  Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous&#xD;
             thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of&#xD;
             anticoagulation is allowed)&#xD;
&#xD;
          -  Patient must not be receiving chronic daily treatment with aspirin (&gt; 325 mg/day) or&#xD;
             non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function.&#xD;
             The use of anti-platelet agents [e.g., dipyridamole (Persantine), ticlopidine&#xD;
             (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving aspirin or&#xD;
             NSAID's known to inhibit platelet function. The use of direct oral anticoagulant&#xD;
             therapies such as dabigatran (Pradaxa) and rivaroxaban (Xarelto) is not allowed while&#xD;
             on study due to bleeding risk&#xD;
&#xD;
          -  Patient must not have a severe infection within 4 weeks prior to randomization,&#xD;
             including, but not limited to, hospitalization for complications of infection,&#xD;
             bacteremia, or severe pneumonia. Patients must not have active tuberculosis&#xD;
&#xD;
          -  Patient must not have a history of non-infectious pneumonitis requiring steroids at&#xD;
             doses greater than or equal to 10 mg per day of prednisone or the equivalent on first&#xD;
             line immunotherapy&#xD;
&#xD;
          -  Patient must not have a history of solid organ transplantation or stem-cell transplant&#xD;
&#xD;
          -  Patient must not be on immunosuppressive medication within 7 days prior to&#xD;
             randomization except for: intranasal, inhaled, or topical steroids, local steroid&#xD;
             injection, systemic corticosteroids at doses less than or equal to 10 mg per day of&#xD;
             prednisone or the equivalent, or steroids used as premedication for hypersensitivity&#xD;
             reactions&#xD;
&#xD;
          -  Patient must not have an active autoimmune disease that requires systemic treatment&#xD;
             within 2 years prior to randomization. Patients who are receiving replacement therapy&#xD;
             for adrenal or pituitary insufficiency will not be excluded&#xD;
&#xD;
          -  Patient must not have had a severe hypersensitivity reaction to any of the drug&#xD;
             components used on this protocol or to chimeric or humanized antibodies or fusion&#xD;
             proteins&#xD;
&#xD;
          -  Patient must not have received any live vaccine within 30 days prior to randomization&#xD;
             and while participating in the study (and continue for 5 months after the last dose of&#xD;
             atezolizumab on Arm C). Live vaccines include, but are not limited to, the following:&#xD;
             measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin&#xD;
             (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated&#xD;
             vaccines and any non-live vaccines including those for the seasonal influenza and&#xD;
             COVID-19 (Note: intranasal influenza vaccines, such as Flu-Mist are live attenuated&#xD;
             vaccines and are not allowed). If possible, it is recommended to separate study drug&#xD;
             administration from vaccine administration by about a week (primarily, in order to&#xD;
             minimize an overlap of adverse events&#xD;
&#xD;
          -  Patient must not be pregnant or breast-feeding due to the potential harm to an unborn&#xD;
             fetus and possible risk for adverse events in nursing infants with the treatment&#xD;
             regimens being used.&#xD;
&#xD;
               -  All patients of childbearing potential must have a blood test or urine study&#xD;
                  within 14 days prior to randomization to rule out pregnancy.&#xD;
&#xD;
               -  A patient of childbearing potential is defined as anyone, regardless of sexual&#xD;
                  orientation or whether they have undergone tubal ligation, who meets the&#xD;
                  following criteria: 1) has achieved menarche at some point, 2) has not undergone&#xD;
                  a hysterectomy or bilateral oophorectomy; or 3) has not been naturally&#xD;
                  postmenopausal (amenorrhea following cancer therapy does not rule out&#xD;
                  childbearing potential) for at least 24 consecutive months (i.e., has had menses&#xD;
                  at any time in the preceding 24 consecutive months)&#xD;
&#xD;
          -  Patients must not expect to conceive or father children by using accepted and&#xD;
             effective method(s) of contraception or by abstaining from sexual intercourse for the&#xD;
             duration of their participation in the study and for 2 months after the last dose of&#xD;
             treatment for patients assigned to Arm A and for 6 months after the last dose of&#xD;
             protocol treatment for patients assigned to Arms B or C.&#xD;
&#xD;
               -  NOTE: Patients must also not breastfeed while on treatment and for 2 months after&#xD;
                  the last dose of treatment for patients assigned to Arm A and for 6 months after&#xD;
                  the last dose of treatment for patients assigned to Arms B or C&#xD;
&#xD;
          -  Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
             requiring recurrent drainage procedures (once monthly or more frequently). Patients&#xD;
             may have indwelling catheters (e.g., PleurX)&#xD;
&#xD;
          -  Patient must not have significant cardiovascular disease (such as New York Heart&#xD;
             Association Class II or greater cardiac disease, myocardial infarction, or&#xD;
             cerebrovascular accident) within 3 months prior to randomization, or unstable&#xD;
             arrhythmia or unstable angina at the time of randomization&#xD;
&#xD;
          -  Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal&#xD;
             therapy (excluding contraceptives and replacement steroids), radiation therapy, or&#xD;
             experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone&#xD;
             metastases or metastases causing nerve impingement) amenable to palliative&#xD;
             radiotherapy should be treated prior to randomization and patients must be recovered&#xD;
             from the effects of radiation (there is no required minimum recovery period&#xD;
&#xD;
          -  Patient must not have had a surgical procedure (including open biopsy, surgical&#xD;
             resection, wound revision, or any other major surgery involving entry into a body&#xD;
             cavity) or significant traumatic injury within 28 days prior to randomization, or&#xD;
             anticipation of need for major surgical procedure while on protocol treatment&#xD;
&#xD;
          -  Patient must not have any other disease, metabolic dysfunction, physical examination&#xD;
             finding, or clinical laboratory finding that contraindicates the use of the agents&#xD;
             used in this protocol, may affect the interpretation of the results, or may render the&#xD;
             patient at high risk from treatment complications&#xD;
&#xD;
          -  Patient must not have a history of abdominal fistula, gastrointestinal (GI)&#xD;
             perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aarti Bhatia</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

